Literature DB >> 22478846

Alzheimer's disease: new therapies and the role of biomarkers.

Kellie Dudash.   

Abstract

Biomarkers have shown promise for identifying people at high risk for Alzheimer's disease. Therapies that address presymptomatic disease are already in development, and MCOs should start thinking about coverage for them.

Entities:  

Year:  2011        PMID： 22478846      PMCID： PMC3086124     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  6 in total

Review 1.  NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.

Authors:  Martha L Daviglus; Carl C Bell; Wade Berrettini; Phyllis E Bowen; E Sander Connolly; Nancy Jean Cox; Jacqueline M Dunbar-Jacob; Evelyn C Granieri; Gail Hunt; Kathleen McGarry; Dinesh Patel; Arnold L Potosky; Elaine Sanders-Bush; Donald Silberberg; Maurizio Trevisan
Journal:  NIH Consens State Sci Statements       Date:  2010-04-28

Review 2.  Alzheimer's disease: clinical trials and drug development.

Authors:  Francesca Mangialasche; Alina Solomon; Bengt Winblad; Patrizia Mecocci; Miia Kivipelto
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

3.  Specialty pharmacy cost management strategies of private health care payers.

Authors:  Debbie Stern; Debi Reissman
Journal:  J Manag Care Pharm       Date:  2006 Nov-Dec

Review 4.  REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

Authors:  Francesco Panza; Vincenza Frisardi; Bruno P Imbimbo; Cristiano Capurso; Giancarlo Logroscino; Daniele Sancarlo; Davide Seripa; Gianluigi Vendemiale; Alberto Pilotto; Vincenzo Solfrizzi
Journal:  CNS Neurosci Ther       Date:  2010-06-16       Impact factor: 5.243

5.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

Review 6.  APOE genotype effects on Alzheimer's disease onset and epidemiology.

Authors:  J Wesson Ashford
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444
  6 in total
  1 in total

1.  Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.

Authors:  Jiansong Fang; Ranyao Yang; Li Gao; Shengqian Yang; Xiaocong Pang; Chao Li; Yangyang He; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2014-12-16       Impact factor: 2.943
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.